Rapid accumulation and internalization of radiolabeled herceptin in an inflammatory breast cancer xenograft with vasculogenic mimicry predicted by the contrast-enhanced dynamic MRI with the macromolecular contrast agent G6-(1B4M-Gd)256

Cancer Research

Volumn 62, Issue 3, 2002, Pages 860-866

  Kobayashi, Hisataka ^a   Shirakawa, Kazuo ^a   Togashi, Kaori ^a   Saga, Tsuneo ^b   Sato, Noriko ^b   Hiraga, Akira ^b   Konishi, Junji ^b   Kawamoto, Satomi ^c   Watanabe, Ichiro ^c   Heike, Yuji ^c   Wakasugi, Hiro ^c   Brechbiel, Martin W ^d  

^a HITACHI LTD   (Japan)

^b Diagnostic Imaging and Nuclear Medicine   (Japan)

^c NATIONAL CANCER CENTER RESEARCH INSTITUTE   (Japan)

^d NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DENDRIMER [2 (4 ISOTHIOCYANATOBENZYL) 6 METHYLDIETHYLENETRIAMINEPENTAACETIC ACID GADOLINIUM]; INDIUM 111; IODINE 125; NUCLEAR MAGNETIC RESONANCE IMAGING AGENT; ONCOPROTEIN; TRASTUZUMAB; UNCLASSIFIED DRUG;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BREAST CANCER; CONTRAST ENHANCEMENT; CONTROLLED STUDY; DRUG ACCUMULATION; DRUG DISTRIBUTION; DRUG LABELING; DRUG TISSUE LEVEL; ENDOTHELIUM CELL; FEMALE; ISOTOPE LABELING; MACROMOLECULE; MAGNETIC RESONANCE ANGIOGRAPHY; MOLECULAR SIZE; MOUSE; NONHUMAN; ONCOGENE NEU; PREDICTION; PRIORITY JOURNAL; TISSUE PERFUSION; TUMOR BLOOD FLOW; TUMOR XENOGRAFT;

ANIMALS; ANTIBODIES, MONOCLONAL; BREAST NEOPLASMS; CONTRAST MEDIA; HUMANS; INDIUM RADIOISOTOPES; MAGNETIC RESONANCE ANGIOGRAPHY; MICE; MICE, NUDE; NEOPLASM TRANSPLANTATION; NEOVASCULARIZATION, PATHOLOGIC; ORGANOMETALLIC COMPOUNDS; RADIOPHARMACEUTICALS; TISSUE DISTRIBUTION; TRANSPLANTATION, HETEROLOGOUS;

EID: 0036468260     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (42)

1. Rapid tumor penetration of a single-chain Fv and comparison with other immunoglobulin forms
2. Improved clearance of radiolabeled biotinylated monoclonal antibody following the infusion of avidin as a chase without decreased accumulation in the target tumor
3. Targeting cancer micrometastases with monoclonal antibodies: A binding-site barrier
4. Radiolabeled-antibody therapy of B-cell lymphoma with autologous bone marrow support
5. Treatment of advanced solid tumors with immunotoxin LMB-1: An antibody linked to Pseudomonas exotoxin
6. Radioimmunotherapy of interleukin-2R α-expressing adult T-cell leukemia with yttrium-90-labeled anti-Tac
7. 99mTc-labeled anti-Tac dsFv
8. Responses in refractory hairy cell leukemia to a recombinant immunotoxin
9. 125I-labeled antiTac single-chain Fv recombinant immunotoxin
10. Accumulation of a recombinant immunotoxin in a tumor in vivo: Fewer than 1000 molecules per cell are sufficient for complete responses
11. Iodine-131-anti-B1 radioimmunotherapy for B-cell lymphoma
12. Radioimmunotherapy with iodine (131)1 tositumomab for relapsed or refractory B-cell non-Hodgkin lymphoma: Updated results and long-term follow-up of the University of Michigan experience
13. Phase I/II clinical radioimmunotherapy with an iodine-131-labeled anti-carcinoembryonic antigen murine monoclonal antibody IgG
14. Absence of endothelial cells, central necrosis, and fibrosis are associated with aggressive inflammatory breast cancer
15. Angiogenic factors
16. Tumor angiogenesis and metastasis: Correlation in invasive breast carcinoma
17. Transplantation of ex vivo expanded endothelial progenitor cells for therapeutic neovascularization
18. Angiogenesis and vasculogenesis as therapeutic strategies for postnatal neovascularization
19. Ischemia- and cytokine-induced mobilization of bone marrow-derived endothelial progenitor cells for neovascularization
20. Transplanted cord blood-derived endothelial precursor cells augment postnatal neovascularization
21. Vascular channel formation by human melanoma cells in vivo and in vitro: Vasculogenic mimicry
22. Molecular biology of breast cancer metastasis. Molecular expression of vascular markers by aggressive breast cancer cells
23. Hemodynamics in vasculogenic mimicry and angiogenesis of inflammatory breast cancer xenograft
24. Starburst dendrimers: Molecular-level control of size, shape, surface chemistry, topology, and flexibility from atoms to macroscopic matter
25. 3D-micro-MR angiography of mice using macromolecular MR contrast agents with polyamidoamine dendrimer core with references to their pharmacokinetic properties
26. Comparison of the macromolecular MR contrast agents with ethylenediamine-core versus ammonia-core generation-6 polyamidoamine dendrimer
27. Three-dimensional structure of Fab R19.9, a monoclonal murine antibody specific for the p-azobenzenearsonate group
28. Three-dimensional structure of antibodies
29. Preliminary crystallographic study of a complex between an heteroclitic anti-hen egg-white lysozyme antibody and the heterologous antigen pheasant egg-white lysozyme
30. Non-small-cell lung carcinoma tumor growth without morphological evidence of neo-angiogenesis
31. Metal-chelatedendrimer-antibody constructs for use in radioimmunotherapy and imaging
32. A human/mouse chimeric monoclonal antibody against CA125 for radioimmunoimaging of ovarian cancer
33. Evaluation of the in vivo biodistribution of indium-111 and yttrium-88 labeled dendrimer-1B4M-DTPA and its conjugation with anti-Tac monoclonal antibody
34. A novel intravascular macromolecular MR contrast agent with generation-4 polyamidoamine dendrimer core: Accelerated renal excretion with co-injection of lysine
35. 3D MR angiography of intratumoral vasculature using a macromolecular MR contrast agent
36. Node-negative breast cancers with p53(-)/HER2-neu(-) status may identify women with very good prognosis
37. Immunohistochemical detection of HER2/neu in patients with axillary lymph node negative breast carcinoma. A study of epidemiologic risk factors, histologic features, and prognosis
38. Herceptin in the adjuvant setting: Phase III trials begin
39. Phase II study of weekly intravenous trastuzumab (Herceptin) in patients with HER2/neu-overexpressing metastatic breast cancer
40. Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185HER2/neu monoclonal antibody plus cisplatin in patients with HER2/neu-over-expressing metastatic breast cancer refractory to chemotherapy treatment
41. Immunoconjugates of geldanamycin and anti-HER2 monoclonal antibodies: Antiproliferative activity on human breast carcinoma cell lines
42. 125I radiolabeled T101 anti-CD5 monoclonal antibody